Skip to main content

Table 2 FEV1 Measures

From: Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

Subject Group

Mean, liters ± SD

Median, liters

Range, liters (min - max)

Baseline FEV 1

   

All patients (n = 95)

1.40 ± 0.71

1.19

3.09 (0.44 - 3.53)

ceftaz/tobra treated (n = 50)

1.37 ± 0.71

1.13

3.09 (0.44 - 3.53)

mero/tobra treated (n = 45)

1.44 ± 0.71

1.37

2.99 (0.48 - 3.47)

FEV1 ≥ 70% predicted (n = 11)

2.46 ± 0.87

2.72

2.38 (1.15 - 3.53)

FEV1 40% - 69% predicted (n = 46)

1.54 ± 0.56

1.47

2.52 (0.56 - 3.08)

FEV1 < 40% predicted (n = 38)

0.93 ± 0.30

0.90

1.43 (0.44 - 1.87)

Observed Peak FEV 1

   

All patients

1.95 ± 0.87

1.72

3.62 (0.67 - 4.29)

ceftaz/tobra treated

1.83 ± 0.85

1.55

3.29 (0.67 - 3.96)

mero/tobra treated

2.09 ± 0.88

1.78

2.99 (0.48 - 4.29)

FEV1 ≥ 70% predicted

3.17 ± 1.01

3.71

2.99 (1.30 - 4.29)

FEV1 40% - 69% predicted

2.05 ± 0.71

2.05

2.76 (0.84 - 3.60)

FEV1 < 40% predicted

1.48 ± 0.59

1.39

2.44 (0.67 - 3.11)

FEV 1 Change, Baseline to Peak

   

All patients

0.55 ± 0.43

0.46

2.19 (0.0 - 2.19)

ceftaz/tobra treated

0.46 ± 0.36

0.39

1.50 (0.05 - 1.55)

mero/tobra treated

0.65 ± 0.49

0.55

2.19 (0.0 - 2.19)

FEV1 ≥ 70% predicted

0.70 ± 0.46

0.43

1.40 (0.15 - 1.55)

FEV1 40% - 69% predicted

0.51 ± 0.41

0.46

2.19 (0.0 - 2.19)

FEV1 < 40% predicted

0.56 ± 0.45

0.43

1.93 (0.01 - 1.94)